|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,148.00 JPY | +0.28% |
|
+0.07% | +2.63% |
| 07-13 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,848B 23.74B 20.75B 19.15B 17.6B 33.35B 2,284B 33.92B 229B 89.69B 1,116B 89.15B 87.2B | P/E 2027 * |
11.2x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,704B 22.85B 19.98B 18.43B 16.94B 32.1B 2,199B 32.65B 220B 86.33B 1,075B 85.82B 83.93B | EV / Sales 2027 * |
1.64x | EV / Sales 2028 * | 1.63x |
| Free-Float |
97.66% | Yield 2027 * |
3.75% | Yield 2028 * | 3.86% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.28% | ||
| 1 week | +0.07% | ||
| Current month | -1.24% | ||
| 1 month | -0.21% | ||
| 3 months | -17.56% | ||
| 6 months | -6.69% | ||
| Current year | +2.63% |
| 1 week | 2,109 |  | 2,176 |
| 1 month | 2,105 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,422.5 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.28% | +0.07% | +48.96% | +7.13% | 23.67B | |
| +2.09% | -3.04% | +49.40% | +163.90% | 1,031B | |
| +0.88% | -3.95% | +51.02% | +56.44% | 595B | |
| +2.78% | +0.39% | +31.64% | +86.07% | 431B | |
| +0.42% | -1.16% | +29.43% | +23.64% | 326B | |
| +1.03% | -0.84% | +29.58% | +45.15% | 277B | |
| +0.49% | -5.44% | +21.00% | +23.80% | 263B | |
| +1.59% | +4.89% | -22.56% | -37.35% | 224B | |
| +2.57% | +1.36% | +23.26% | +61.77% | 193B | |
| +0.88% | -1.23% | +21.24% | +71.89% | 164B | |
| Average | +1.24% | -3.43% | +28.30% | +50.24% | 352.8B | |
| Weighted average by Cap. | +1.47% | -4.28% | +34.68% | +79.85% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,258B 13.93B 12.18B 11.23B 10.33B 19.57B 1,340B 19.9B 134B 52.62B 655B 52.31B 51.16B | 2,074B 12.8B 11.19B 10.32B 9.49B 17.98B 1,231B 18.28B 123B 48.34B 602B 48.05B 47B |
| Net income | 344B 2.12B 1.86B 1.71B 1.57B 2.98B 204B 3.03B 20.43B 8.02B 99.79B 7.97B 7.79B | 327B 2.02B 1.77B 1.63B 1.5B 2.84B 194B 2.89B 19.45B 7.63B 95B 7.59B 7.42B |
| Net Debt | -144B -888M -776M -716M -658M -1.25B -85.41B -1.27B -8.55B -3.35B -41.75B -3.33B -3.26B | -458B -2.82B -2.47B -2.28B -2.09B -3.97B -272B -4.04B -27.2B -10.67B -133B -10.61B -10.38B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | JP¥2,148.00 | +0.28% | 7,147,600 |
| 15/07/26 | JP¥2,142.00 | -0.19% | 6,310,600 |
| 14/07/26 | JP¥2,146.00 | +1.18% | 5,802,100 |
| 13/07/26 | JP¥2,121.00 | -0.98% | 4,304,400 |
| 10/07/26 | JP¥2,142.00 | +0.21% | 5,971,100 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
